Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response contains general, label-consistent statements about FYCOMPA (perampanel) being an antiepileptic and commonly used as add-on therapy, but the specific indication and “add-on” characterization are not verifiable from the provided label excerpts, and no dosing/contraindications/boxed warning details were evaluated.
Category Scores
Accurate Statements
Fycompa es el nombre comercial de perampanel.
Supported by provided context identifying FYCOMPA (perampanel).
Perampanel es un fármaco antiepiléptico.
Supported insofar as the label excerpt refers to FYCOMPA as an AED (Antiepileptic drugs (AEDs), including FYCOMPA...).
Unsupported Statements
Fycompa se usa para tratar convulsiones en personas con epilepsia.
The provided label excerpts include warnings/adverse reaction information but do not explicitly state the approved indication(s) or that the use is for convulsions in people with epilepsy.
Fycompa se usa por lo general como terapia add-on, sumado a otros tratamientos.
The provided excerpts do not explicitly describe the approved use as add-on therapy; they discuss controlled trials (e.g., partial-onset seizure trials) and counseling but do not state the indication/adjunctive nature.
Contradictions
Important Omissions
No information was provided regarding contraindications, boxed warning content, dose/administration, alcohol/CNS depressant precautions, or monitoring recommendations (e.g., psychiatric monitoring and avoiding alcohol) from the included label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety-related label content (e.g., serious psychiatric/behavioral reactions, suicidal behavior/ideation, alcohol/CNS depressant cautions, and monitoring) was not addressed in the claims, and two efficacy/indication-style claims were not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Indication/add-on-use claims are not supported by the label excerpts provided, and safety/monitoring/alcohol precautions from the excerpts were omitted.
Suggested Improvement
Limit claims to what is explicitly supported by the supplied label sections (e.g., that FYCOMPA is an AED and the provided warnings/monitoring/alcohol/CNS depressant cautions), or provide the specific label indication section(s) to substantiate the approved use and adjunctive description.